Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
DENVER, April 17, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its first quarter 2017 financial results on Thursday, May 4, 2017, before the opening of the U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Jeffrey M. Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | Thursday, May 4, 2017 | |
| Time | 9:00 a.m. EDT | |
| Toll free (U.S.) | (888) 372-9592 | |
| Webcast (live and replay) | www.bioscrip.com | |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 8579499.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts: Jeffrey M. Kreger Chief Financial Officer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]
